Physician profile
Curt Mcclellan
NPI 1558331389
$269.18
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $76.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.32 | 2021 | |
| Novo Nordisk INC | $39.94 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.13 | 2021 | |
| Ironwood Pharmaceuticals, INC | $31.21 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.08 | 2022 | |
| Grifols USA, LLC | $17.55 | 2022 | |
| Glaxosmithkline, LLC. | $16.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.64 | 2021 | |
| Amgen INC. | $16.30 | 2022 | |
| Virtus Pharmaceuticals LLC | $15.22 | 2021 | |
| Amarin Pharma, INC. | $11.11 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curt Mcclellan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.